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N-aryl(benzyl,heteryl)-2-(tet-
razolo[1,5-c]quinazolin-5-
ylthio)acetamidesAbstract The death rate from cancer and infectious diseases is still very high, therefore research
in this area is extremely important and promising as in medical, so in economic point of view.
Thus, potassium salt of tetrazolo[1,5-c]quinazolin-5-thion was modiﬁed per alkylation by
N-aryl(benzyl,heteryl)acetamides with proper conﬁrmation of newly synthesized compounds’
structures by FT-IR, LC–MS, 1H NMR and elemental analysis data. The substances were tested
for bioluminescence inhibition against Photobacterium leiognathi Sh1 (5–50 lg/mL) to check their
cytotoxicity. Then they were screened for antibacterial and antifungal activities (100 lg) against
Escherichia coli, Staphylococcus aureus, Enterobacter aerogenes and Enterococcus faecalis,
Pseudomonas aeruginosa, Klebsiella pneumoniae and Candida albicans. It was found that compounds
1.1, 1.5, 1.10, 1.31, 1.33 possessed light activity against K. pneumonia. The US National Cancer
Institute (NCI) has chosen 19 compounds and screened them for ability to inhibit in 10 lM
concentration 60 different human tumor cell lines. The LOX IMVI cell line of melanoma appeared
to be the most sensitive one, and N-(6-methylbenzo[d]thiazol-2-yl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.31) and N-(3-ﬂuorobenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)acetamide
(1.19) exhibited high growth inhibition rate, and N-(6-methoxybenzo[d]thiazol-2-yl)-2-(tetrazol-
o[1,5-c]quinazolin-5-ylthio)acetamide (1.32) showed lethal antitumor activity against it. The latter
compound 1.32 showed the best anticancer results, also inhibiting growth of leukemia SR cell line,
Potential of N-aryl(benzyl,heteryl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)acetamides 793NCI-H460 of non-small cell lung cancer, KM12 of colon cancer and SF-295 of CNS cancer. The in
silico molecular docking studies have predicted the afﬁnity of the synthesized substances to the epi-
dermal growth factor receptor (EGFR).
ª 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Annually in the world about 13 million of new oncological
cases are registered and more than 6.2 million deaths occur,
according to WHO data. As you can see, death rate is very
high. The situation with bacterial infections is no better. The
WHO report of 2014 about antimicrobial resistance warns that
resistance to common bacteria, viruses and fungi has reached
alarming levels in many parts of the world, and a post-antibi-
otic era, in which common infections and minor injuries can
kill, is a very real possibility for the 21st Century. Nevertheless,
more and more people are surviving cancer, thanks to
advances in treatment and screening tests that could predict
or detect it. That is why anticancer and antimicrobial agent
investigations are very important and always up-to-date. Our
research group is dealing with substituted tetrazolo[1,5-c]
quinazolines (Antypenko et al., 2013), [1,2,4]triazolo[1,5-c]
quinazolines (Antipenko et al., 2009a,b) and [1,2,4]triazino
[2,3-c]quinazolines (Nosulenko et al., 2014; Berest et al.,
2011, 2012; Kovalenko et al., 2012), that were already
investigated to have various biological activities: antibacterial,
antifungal, anticancer, antiviral and antioxidant. The potent
EGFR inhibitors – anticancer drugs such as Geﬁtinib,
Erlotinib, Lapatinib, Vandetanib or Saracatinib (Cao et al.,
2006; Carlomagno et al., 2002; Konecny et al., 2006; Rusnak
et al., 2001) are quinazoline derivatives from chemical aspect.
Thus, 2-(tetrazolo[1,5-c]quinazolin-5-ylthio)-1-(p-tolyl)etha-
none showed lethal leukemia CCRF-CEM cell line growth
inhibition (49.78 growth percent), 3-(tetrazolo[1,5-c]quinazo-
lin-5-ylthio)propanoic acid to 44.08%, 3-methyl-2-(tetrazolo
[1,5-c]quinazolin-5-ylthio)butanoic acid to 55.61%, and
methyl (tetrazolo[1,5-c]quinazolin-5-ylthio)acetate to 32.45%
(Antypenko et al., 2013). Moreover, condensed tetrazoles:
tetrazolo[1,5-a]quinoline-4-carbonitriles (Kategaonkar et al.,
2010), dihydrotetrazoloquinazolines and dihydrotetrazoloqui-
nazolinones (Ellis et al., 1980; Jantova et al., 2004;
Mohammed et al., 1991; Myznikov et al., 2007; Sherif et al.,
2009) revealed antimicrobial activity. Among all the chemical
structure modiﬁcations and introductions of the different func-
tional residues into the main skeleton, the acetamide synthesis
was chosen, since it was found, that N-cyclohexyl-2-[5-(4-pyri-
dyl)-4-(p-tolyl)-4H-1,2,4-triazol-3-ylsulfanyl]acetamide dihydrate
had been synthesized and demonstrated good antibacterial
(Escherichia coli, Staphylococcus aureus, Pseudomonas
aeruginosa and Klebsiella pneumonia), antifungal (Aspergillus
ﬂavus, Aspergillus fumigatus, Penicillium marneffei and
Trichophyton mentagrophytes) and antioxidant activities
(Orek et al., 2012). Moreover, 4-phenyl-1-napthyl phenyl acet-
amide showed antifungal (Aspergillus, Candida species) activity
(Saha et al. 2012); some 2-morpholino-N-(4,6-diarylpyrimidin-
2-yl)acetamides were strong antibacterial (b-Hemolytic
streptococcus and K. pneumonia, E. coli and Pseudomonas)
and antifungal (A. ﬂavus, Microsporum gypseum, Mucor,Rhizopus) agents (Kanagarajan et al., 2010); and benzimidaz-
olyl-1,3,4-oxadiazol-2-ylthio-N-phenyl(benzothiazolyl)aceta-
mides possessed antibacterial (S. aureus, Bacillus cereus, E. coli,
P. aeruginosa, K. pneumoniae, Salmonella typhi, Proteus
vulgaris, Shigella ﬂexneri) and antitubercular (Mycobacterium
tuberculosis) properties (Patel et al., 2012). Hence, the aim of
this research is to unleash the potential of novel N-aryl
(benzyl,heteryl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)acetamides
as antibacterial, antifungal and anticancer agents.2. Experimental
Melting points were determined in open capillary tubes in a
«Stuart SMP30» apparatus and were uncorrected. The elemen-
tal analyses (C, H, N, S) were performed using the ELEMEN-
TAR vario EL cube analyzer. IR spectra (4000–600 cm1) were
recorded on a Bruker ALPHA FT-IR spectrometer using a
module ATR eco ZnSe. 1H NMR spectra (400 MHz) were
recorded at a Varian-Mercury 400 and Bruker Avance DRX-
500 spectrometers with SiMe4 as internal standard in DMSO-
d6 solution. LC–MS were recorded using chromatography/
mass spectrometric system which consists of high-performed
liquid chromatograph «Agilent 1100 Series» equipped with
diode-matrix and mass-selective detector «Agilent LC/MSD
SL» (atmospheric pressure chemical ionization – APCI).
2.1. General procedure for the synthesis of N-aryl(benzyl,
heteryl)-2-(tetrazolo[1,5-c]quinazoline-5-ylthio)acetamides
Method A: N,N-Carbonyldiimidazole (0.71 g, 4.4 mmol) was
added to a solution of 2-(tetrazolo[1,5-c]quinazolin-5-ylthio)
acetic acid (4.4 mmol) in 10 ml of anhydrous 1,4-dioxane and
heated at the water bath at 60–80 C for 1 h with calcium chlo-
ride tube. Then the proper N-aryl(benzyl,heteryl)-amine
(4.4 mmol) was added to the resulting mixture and reﬂuxed
for 1 h with stirring. The mixture was poured into the water,
neutralized to pH 6–7 by NaOH. The precipitate was ﬁltered,
dried and recrystallized from the mixture of 2-propanol:water
(2:1).
Method B: N-aryl(benzyl,heteryl)-2-chloroacetamide
(4.4 mmol) was added to a suspension of tetrazolo[1,5-C]qui-
nazoline-5-thione potassium salt (4.4 mol) in 20 ml of 2-propa-
nol and reﬂuxed for 2 h. The mixture was cooled and poured
into the water. The precipitate was ﬁltered, dried and recrystal-
lized from mixture of 2-propanol:water (2:1).
2.1.1. N-(2-Methoxyphenyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.1)
Yield = 85%; mp = 170–172 C; 1H NMR: d (ppm): 9.56 (s,
1H, NH), 8.55 (d, J= 7.81 Hz, 1H, H-10), 8.05 (t,
J= 7.51 Hz, 2H, H-7, Ph-6), 8.00 (t, J= 7.67 Hz, 1H, H-9),
7.82 (t, J= 7.36 Hz, 1H, H-8), 7.03 (t, J= 7.51 Hz, 1H,
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1H, Ph-5), 4.51 (s, 2H, SCH2), 3.81 (s, 3H, OCH3). IR
(cm1): 3343, 2918, 2848, 1676, 1619, 1587, 1536, 1488, 1455,
1435, 1390, 1327, 1291, 1277, 1248, 1214, 1173, 1144, 1124,
1109, 1051, 1037, 1020, 983, 969, 930, 898, 875, 783, 771,
741, 714, 677, 669, 648. LC–MS: m/z= 367 [M+H]+. Anal.
Calcd. for C17H14N6O2S: C, 55.73; H, 3.85; N, 22.94; S,
8.75. Found: C, 55.71; H, 3.89; N, 22.90; S, 8.79.
2.1.2. N-(3-Methoxyphenyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.2)
Yield = 99%; mp = 168–170 C; 1H NMR: d (ppm) 10.40 (s,
1H, NH), 8.53 (d, J= 7.66 Hz, 1H, H-10), 8.00–7.93 (m, 2H,
H-7,9), 7.79 (t, J= 7.08 Hz, 1H, H-8), 7.33 (s, 1H, Ph-2), 7.16
(dd, J= 18.72, 7.83 Hz, 2H, Ph-5,6), 6.60 (d, J= 6.67 Hz,
1H, Ph-4), 4.46 (s, 2H, SCH2), 3.75 (s, 3H, OCH3). IR
(cm1): 3263, 3199, 3118, 3058, 3023, 2961, 2919, 2866, 2849,
2849, 2838, 1681, 1621, 1587, 1540, 1489, 1478, 1451, 1426,
1386, 1325, 1301, 1280, 1260, 1202, 1179, 1164, 1145, 1104,
1080, 1050, 1036, 973, 956, 897, 885, 872, 861, 807, 769, 750,
713, 687, 637, 616. LC–MS: m/z= 367 [M+H]+. Anal.
Calcd. for C17H14N6O2S: C, 55.73; H, 3.85; N, 22.94; S,
8.75. Found: C, 55.79; H, 3.81; N, 22.97; S, 8.75.
2.1.3. N-(4-Methoxyphenyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.3)
Yield = 98%; mp = 176–178 C; 1H NMR: d (ppm): 10.24 (s,
1H, NH), 8.54 (d, J= 7.5 Hz, 1H, H-10), 8.01–7.95 (m, 2H,
H-7,9), 7.80 (t, J= 6.7 Hz, 1H, H-8), 7.52 (d, J= 7.4 Hz,
2H, Ph-2,6), 6.83 (d, J= 7.1 Hz, 2H, Ph-3,5), 4.43 (s, 2H,
SCH2), 3.75 (s, 3H, OCH3). IR (cm
1): 3325, 3256, 3198,
3059, 3005, 2961, 2919, 2851, 1676, 1657, 1619, 1590, 1537,
1511, 1493, 1475, 1462, 1452, 1439, 1414, 1382, 1325, 1288,
1276, 1248, 1237, 1194, 1159, 1108, 1036, 1027, 984, 970,
872, 827, 808, 793, 770, 715, 688, 668, 646, 614, 614.
LC–MS: m/z= 367 [M+H]+. Anal. Calcd. for C17H14N6O2S:
C, 55.73; H, 3.85; N, 22.94; S, 8.75. Found: C, 55.71; H, 3.89;
N, 22.90; S, 8.79.
2.1.4. N-(2-Fluorophenyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.4)
Yield = 82%; mp = 196–198 C; 1H NMR: d (ppm) 10.19 (s,
1H, NH), 8.55 (d, J= 7.61 Hz, 1H, H-10), 8.00 (dd,
J= 12.21, 6.92 Hz, 3H, H-7,9, Ph-6), 7.82 (t, J= 7.06 Hz,
1H, H-8), 7.22–7.07 (m, 3H, Ph-3,4,5), 4.53 (s, 2H, SCH2).
IR (cm1): 3323, 3258, 2998, 2920, 2850, 1660, 1619, 1590,
1538, 1495, 1475, 1453, 1405, 1382, 1323, 1276, 1258, 1194,
1160, 1137, 1103, 1036, 980, 969, 942, 905, 872, 855, 836,
803, 766, 754, 715, 688, 668, 642, 616. LC–MS: m/z= 355
[M+H]+. Anal. Calcd. for C16H11FN6OS: C, 54.23; H, 3.13;
N, 23.72; S, 9.05. Found: C, 54.26; H, 3.12; N, 23.79; S, 9.01.
2.1.5. N-(3-Fluorophenyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.5)
Yield = 83%; mp = 212–214 C; 1H NMR: d (ppm) 10.65 (s,
1H, NH), 8.52 (d, J= 7.21 Hz, 1H, H-10), 8.01–7.92 (m, 2H,
H-7,9), 7.78 (t, J= 7.53 Hz, 1H, H-8), 7.59 (d, J= 11.20 Hz,
1H, Ph-6), 7.40–7.23 (m, 2H, Ph-4,5), 6.79 (s, 1H, Ph-2), 4.47
(s, 2H, SCH2). IR (cm
1): 3274, 2919, 2850, 1734, 1682,
1636, 1615, 1587, 1540, 1506, 1489, 1474, 1443, 1374, 1323,1270, 1254, 1185, 1162, 1147, 1131, 1107, 1041, 1022, 1001,
985, 964, 919, 895, 867, 809, 770, 711, 684, 651, 638.
LC–MS: m/z= 355 [M+H]+. Anal. Calcd. for C16H11FN6OS:
C, 54.23; H, 3.13; N, 23.72; S, 9.05. Found: C, 54.19; H, 3.17;
N, 23.69; S, 9.09.
2.1.6. N-(4-Fluorophenyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.6)
Yield = 77%; mp = 182–184 C; 1H NMR: d (ppm) 10.44 (s,
1H, NH), 8.55 (d, J= 7.65 Hz, 1H, H-10), 8.02–7.94 (m, 2H,
H-7,9), 7.80 (t, J= 7.06 Hz, 1H, H-8), 7.68–7.59 (m, 2H,
Ph-2,6), 7.05 (t, J= 8.00 Hz, 2H, Ph-3,5), 4.45 (s, 2H,
SCH2). IR (cm
1): 3353, 3065, 2921, 2850, 1732, 1684, 1673,
1641, 1618, 1587, 1542, 1511, 1495, 1479, 1454, 1408, 1384,
1329, 1281, 1254, 1228, 1217, 1160, 1109, 1043, 976, 891, 882,
870, 832, 810, 786, 770, 715, 686, 668, 636, 616. LC–MS:
m/z= 355 [M+H]+. Anal. Calcd. for C16H11FN6OS: C,
54.23; H, 3.13; N, 23.72; S, 9.05. Found: C, 54.27; H, 3.10;
N, 23.75; S, 9.02.
2.1.7. N-(2-Chlorophenyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.7)
Yield = 76%; mp = 180–182 C; 1H NMR: d (ppm) 9.87 (s,
1H, NH), 8.55 (d, J= 6.37 Hz, 1H, H-10), 8.04 (d,
J= 4.78 Hz, 1H, H-7), 7.98 (d, J= 5.37 Hz, 1H, H-9),
7.89–7.76 (m, 2H, H-8, Ph-6), 7.43 (d, J= 6.10 Hz, 1H,
Ph-3), 7.29 (d, J= 5.03 Hz, 1H, Ph-5), 7.16 (d, J= 4.77 Hz,
1H, Ph-4), 4.55 (s, 2H, SCH2). IR (cm
1): 3745, 3609, 3244,
3004, 2929, 2852, 2177, 2089, 1690, 1654, 1619, 1588, 1564,
1534, 1489, 1474, 1451, 1441, 1382, 1320, 1275, 1238, 1212,
1159, 1139, 1108, 1058, 1036, 983, 969, 938, 907, 874, 840,
769, 753, 737, 717, 688, 679, 668, 642, 615. LC–MS:
m/z= 371 [M+H]+. Anal. Calcd. for C16H11ClN6OS: C,
51.82; H, 2.99; N, 22.66; S, 8.65. Found: C, 51.80; H, 3.04;
N, 22.64; S, 8.67.
2.1.8. N-(3-Chlorophenyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.8)
Yield = 75%; mp = 182–184 C; 1H NMR: d (ppm) 10.58 (s,
1H, NH), 8.54 (d, J= 7.8 Hz, 1H, H-10), 7.97 (s, 2H, H-7,9),
7.80 (s, 2H, H-8, Ph-2), 7.50 (d, J= 7.9 Hz, 1H, Ph-6), 7.30 (t,
J= 7.4 Hz, 1H, Ph-5), 7.05 (d, J= 7.6 Hz, 1H, Ph-4), 4.47 (s,
2H, SCH2). IR (cm
1): 3745, 3325, 3290, 3197, 3131, 3110,
3058, 2953, 2953, 2953, 2921, 2851, 1689, 1642, 1616, 1596,
1588, 1543, 1486, 1453, 1410, 1389, 1379, 1328, 1279, 1238,
1166, 1109, 1080, 1041, 996, 985, 974, 881, 787, 772, 713,
699, 684, 638, 604. LC–MS: m/z= 371 [M+H]+. Anal.
Calcd. for C16H11ClN6OS: C, 51.82; H, 2.99; N, 22.66; S,
8.65. Found: C, 51.78; H, 2.94; N, 22.67; S, 8.64.
2.1.9. N-(4-Chlorophenyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.9)
Yield = 67%; mp = 202–206 C; 1H NMR: d (ppm) 10.55 (s,
1H, NH), 8.55 (d, J= 7.7 Hz, 1H, H-10), 7.98 (s, 2H, H-7,9),
7.83–7.77 (m, 1H, H-8), 7.66 (d, J= 8.5 Hz, 2H, Ph-2,6), 7.29
(d, J= 8.4 Hz, 2H, Ph-3,5), 4.46 (s, 2H, SCH2). IR (cm
1):
3857, 3745, 3351, 3129, 3063, 2926, 2850, 1731, 1672, 1641,
1619, 1588, 1538, 1493, 1454, 1402, 1388, 1329, 1277, 1242,
1209, 1191, 1166, 1108, 1094, 1043, 1012, 976, 963, 891, 883,
865, 824, 787, 772, 733, 716, 687, 668, 646, 627, 616.
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OS: C, 51.82; H, 2.99; N, 22.66; S, 8.65. Found: C, 51.80; H,
3.01; N, 22.65; S, 8.69.
2.1.10. N-(2-Bromophenyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.10)
Yield = 22%; mp = 156–160 C; 1H NMR: d (ppm) 9.79 (s,
1H, NH), 8.56 (d, J= 7.47 Hz, 1H, H-10), 8.07 (d,
J= 7.78 Hz, 1H, H-7), 8.00 (t, J= 6.72 Hz, 1H, H-9), 7.83
(t, J= 7.17 Hz, 1H, H-8), 7.75 (d, J= 6.91 Hz, 1H, Ph-6),
7.61 (d, J= 7.60 Hz, 1H, Ph-3), 7.35 (t, J= 7.67 Hz, 1H,
Ph-5), 7.11 (d, J= 5.98 Hz, 1H, Ph-4), 4.53 (s, 2H, SCH2).
IR (cm1): 3747, 3244, 3003, 2919, 2850, 1654, 1632, 1620,
1589, 1563, 1535, 1491, 1475, 1452, 1438, 1381, 1324, 1276,
1237, 1199, 1161, 1139, 1108, 1037, 983, 970, 877, 877, 839,
769, 753, 732, 717, 688, 668, 659, 643, 615. LC–MS:
m/z= 416 [M+H]+. Anal. Calcd. for C16H11BrN6OS: C,
46.28; H, 2.67; N, 20.24; S, 7.72. Found: C, 46.24; H, 2.69;
N, 20.28; S, 7.70.
2.1.11. N-(3-Bromophenyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.11)
Yield = 72%; mp = 192–194 C; 1H NMR: d (ppm) 10.57 (s,
1H, NH), 8.54 (d, J= 7.5 Hz, 1H, H-10), 7.96 (d,
J= 12.7 Hz, 3H, H-7,9, Ph-2), 7.80 (s, 1H, H-8), 7.55 (d,
J= 7.2 Hz, 1H, Ph-4), 7.30–7.12 (m, 2H, Ph-5,6), 4.46 (s,
2H, SCH2). IR (cm
1): 3311, 3243, 3174, 3131, 3079, 2954,
2919, 2850, 1681, 1659, 1650, 1642, 1632, 1621, 1588, 1564,
1555, 1536, 1503, 1490, 1470, 1453, 1410, 1385, 1317, 1278,
1263, 1238, 1161, 1108, 1081, 1037, 994, 974, 959, 886, 873,
863, 789, 770, 712, 680, 666, 640, 617. LC–MS: m/z= 417
[M+H]+. Anal. Calcd. for C16H11BrN6OS: C, 46.28; H,
2.67; N, 20.24; S, 7.72. Found: C, 46.23; H, 2.66; N, 20.25;
S, 7.71.
2.1.12. N-(4-Bromophenyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.12)
Yield = 83%; mp = 204–206 C; 1H NMR: d (ppm) 10.53 (s,
1H, NH), 8.53 (d, J= 7.6 Hz, 1H, H-10), 7.96 (s, 2H, H-7,9),
7.79 (s, 1H, H-8), 7.60 (d, J= 7.5 Hz, 2H, Ph-2,6), 7.44 (d,
J= 7.6 Hz, Ph-3,5), 4.46 (s, 2H, SCH2). IR (cm
1): 3746,
3310, 3059, 2927, 2852, 2165, 2114, 1785, 1729, 1689, 1673,
1641, 1632, 1620, 1589, 1573, 1536, 1488, 1453, 1387, 1326,
1276, 1242, 1192, 1164, 1108, 1071, 1042, 1008, 973, 962,
882, 821, 786, 771, 728, 715, 687, 668, 636, 614. LC–MS:
m/z= 417 [M+H]+. Anal. Calcd. for C16H11BrN6OS: C,
46.28; H, 2.67; N, 20.24; S, 7.72. Found: C, 46.21; H, 2.65;
N, 20.27; S, 7.76.
2.1.13. N-(3-(Triﬂuoromethyl)phenyl)-2-(tetrazolo[1,5-
c]quinazolin-5-ylthio)acetamide (1.13)
Yield = 71%; mp = 206–208 C; 1H NMR: d (ppm) 9.92 (s,
1H, NH), 8.57 (d, J= 7.82 Hz, 1H, H-10), 8.05–7.98 (m,
2H, H-7,9), 7.83 (t, J= 7.10 Hz, 1H, H-8), 7.70 (d,
J= 7.64 Hz, 1H, Ph-6), 7.63 (t, J= 7.53 Hz, 1H), 7.57 (d,
J= 7.79 Hz, 1H), 7.44 (d, J= 7.14 Hz, 1H), 4.51 (s, 2H,
SCH2). IR (cm
1): 3248, 2997, 2926, 2850, 1657, 1619, 1589,
1537, 1489, 1451, 1381, 1316, 1273, 1238, 1176, 1161, 1106,
1056, 1037, 969, 904, 876, 854, 841, 761, 715, 665, 650, 604.
LC–MS: m/z= 405 [M+H]+. Anal. Calcd. for C17H11F3N6OS: C, 50.49; H, 2.74; N, 20.78; S, 7.93. Found: C, 50.46; H,
2.78; N, 20.74; S, 7.97.
2.1.14. N-(4-(Triﬂuoromethyl)phenyl)-2-(tetrazolo[1,5-
c]quinazolin-5-ylthio)acetamide (1.14)
Yield = 95%; mp = 178–180 C; 1H NMR: d (ppm) 10.72 (s,
1H, NH), 8.54 (d, J= 7.34 Hz, 1H, H-10), 8.07 (s, 1H, H-7),
7.96 (d, J= 7.01 Hz, 2H, H-9, Ph-2), 7.82 (dd, J= 12.66,
7.91 Hz, 2H, H-8, Ph-6), 7.51 (d, J= 7.19 Hz, 1H, Ph-3),
7.34 (d, J= 7.05 Hz, 1H, Ph-5), 4.49 (s, 2H, SCH2). IR
(cm1): 3325, 3296, 3244, 3160, 3115, 3050, 2979, 2923, 2851,
1697, 1617, 1586, 1556, 1494, 1454, 1382, 1336, 1327, 1280,
1238, 1184, 1164, 1132, 1111, 1100, 1076, 1043, 1001, 985,
974, 905, 887, 800, 787, 775, 699, 652, 652, 639, 604. LC–
MS: m/z= 405 [M+H]+. Anal. Calcd. for C17H11F3N6OS:
C, 50.49; H, 2.74; N, 20.78; S, 7.93. Found: C, 50.53; H,
2.71; N, 20.79; S, 7.91.
2.1.15. N-(2-Methoxybenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.15)
Yield = 83%; mp = 186–188 C; 1H NMR: d (ppm): 8.56 (d,
J= 7.78 Hz, 1H, H-10), 8.52 (unsplit, 1H, NH), 8.01–7.94 (m,
2H, H-7,9), 7.81 (t, J= 3.94 Hz, 1H, H-8), 7.20 (d,
J= 7.73 Hz, 1H, Ph-6), 7.16 (d, J= 7.73 Hz, 1H, Ph-3), 6.88
(d, J= 8.03 Hz, 1H, Ph-4), 6.76 (t, J= 7.30 Hz, 1H, Ph-5),
4.33 (d, J= 5.51 Hz, 2H, NHCH2), 4.30 (s, 2H, SCH2), 3.82
(s, 3H, OCH3). IR (cm
1): 3266, 3086, 2998, 2924, 2839, 1646,
1617, 1606, 1586, 1567, 1559, 1521, 1489, 1473, 1466, 1456,
1436, 1395, 1381, 1368, 1324, 1301, 1275, 1245, 1224, 1169,
1160, 1140, 1115, 1106, 1061, 1049, 1035, 1025, 983, 967, 900,
885, 877, 815, 784, 765, 743, 716, 643, 629. LC–MS: m/z=
381 [M+H]+. Anal. Calcd. for C18H16N6O2S: C, 56.83; H,
4.24;N, 22.09; S, 8.43.Found:C, 56.88;H, 4.20;N, 22.13; S, 8.41.
2.1.16. N-(3-Methoxybenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.16)
Yield = 52%; mp = 174–176 C; 1H NMR: d (ppm): 8.75
(unsplit, 1H, NH), 8.54 (d, J= 7.55 Hz, 1H, H-10), 7.98–
7.91 (m, 2H, H-7,9), 7.81 (t, J= 5.68 Hz, 1H, H-8), 7.14 (t,
J= 7.42 Hz, 1H, Ph-2), 6.87–6.79 (m, 2H, Ph-4,6), 6.73 (d,
J= 7.54 Hz, 1H, PH-5), 4.33 (d, J= 5.15 Hz, 2H, NHCH2),
4.29 (s, 2H, SCH2), 3.71 (s, 3H, OCH3). IR (cm
1): 3736,
3275, 3084, 3001, 2960, 2921, 2851, 1724, 1690, 1650, 1615,
1587, 1556, 1519, 1490, 1474, 1453, 1432, 1383, 1325, 1288,
1275, 1263, 1226, 1150, 1108, 1072, 1036, 995, 979, 966, 897,
877, 851, 770, 741, 715, 689, 669, 639. Anal. Calcd. for C18H16-
N6O2S: C, 56.83; H, 4.24; N, 22.09; S, 8.43. Found: C, 56.79;
H, 4.27; N, 22.03; S, 8.48.
2.1.17. N-(4-Methoxybenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.17)
Yield = 76%; mp = 202–204 C; 1H NMR: d (ppm): 8.66
(unsplit, 1H, NH), 8.55 (d, J= 7.41 Hz, 1H, H-10), 7.94 (d,
J= 7.09 Hz, 1H, H-7), 7.90 (d, J= 8.00 Hz, 1H, H-9), 7.81
(t, J= 7.89 Hz, 1H, H-8), 7.18 (d, J= 8.33 Hz, 2H, Ph-2,6),
6.75 (d, J= 8.42 Hz, 2H, Ph-3,5), 4.28 (d, J= 5.74 Hz, 2H,
NHCH2), 4.25 (s, 2H, SCH2), 3.74 (s, 3H, OCH3). IR
(cm1): 3281, 3063, 2989, 2919, 2841, 1744, 1713, 1644, 1614,
1587, 1550, 1513, 1495, 1472, 1463, 1442, 1398, 1378, 1363,
1324, 1306, 1273, 1247, 1220, 1185, 1167, 1137, 1106, 1066,
796 O.M. Antypenko et al.1029, 1007, 979, 969, 875, 843, 819, 785, 768, 716, 680, 641.
LC–MS: m/z= 381 [M+H]+. Anal. Calcd. for C18H16N6O2S:
C, 56.83; H, 4.24; N, 22.09; S, 8.43. Found: C, 56.87; H, 4.28;
N, 22.04; S, 8.39.
2.1.18. N-(2-Fluorobenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.18)
Yield = 74%; mp = 184–186 C; 1H NMR: d (ppm): 8.75
(unsplit, 1H, NH), 8.55 (d, J= 7.84 Hz, 1H, H-10), 7.98–7.93
(m, 2H, H-7,9), 7.81 (dd, J= 7.73, 2.91 Hz, 1H, H-8), 7.34 (t,
J= 7.42 Hz, 1H, Ph-3), 7.23 (dd, J= 12.65, 6.19 Hz, 1H, Ph-
4), 7.06 (d, J= 9.38 Hz, 1H, Ph-6), 7.00 (t, J= 7.72 Hz, 1H,
Ph-5), 4.40 (d, J= 5.47 Hz, 2H, NHCH2), 4.29 (s, 2H SCH2).
IR (cm1): 3376, 3330, 3066, 2926, 2847, 1674, 1615, 1585,
1538, 1488, 1453, 1424, 1380, 1361, 1318, 1275, 1254, 1226,
1201, 1173, 1164, 1108, 1041, 1030, 986, 974, 947, 897, 886,
830, 787, 775, 760, 715, 697, 680, 633. LC–MS: m/z= 369
[M+H]+. Anal. Calcd. for C17H13FN6OS: C, 55.43; H, 3.56;
N, 22.81; S, 8.70. Found: C, 55.47; H, 3.52; N, 22.86; S, 8.67.
2.1.19. N-(3-Fluorobenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.19)
Yield = 76%; mp = 192–196 C; 1H NMR: d (ppm): 8.80
(unsplit, 1H, NH), 8.55 (d, J= 7.73 Hz, 1H, H-10), 7.98–
7.92 (m, 2H, H-7,9), 7.84–7.77 (m, 1H, H-8), 7.27–7.20 (m,
1H, Ph-5), 7.08 (d, J= 7.55 Hz, 1H, Ph-4), 7.04 (d,
J= 9.66 Hz, 1H, Ph-6), 6.92 (t, J= 7.77 Hz, 1H, Ph-2), 4.37
(d, J= 5.46 Hz, 2H, NHCH2), 4.29 (s, 2H, SCH2). IR
(cm1): 3273, 3084, 2985, 2928, 2853, 1650, 1619, 1588, 1555,
1490, 1475, 1452, 1385, 1367, 1327, 1280, 1249, 1225, 1165,
1139, 1110, 1079, 1038, 1026, 983, 970, 930, 887, 875, 864,
767, 746, 713, 688, 645, 630. LC–MS: m/z= 369 [M+H]+.
Anal. Calcd. for C17H13FN6OS: C, 55.43; H, 3.56; N, 22.81;
S, 8.70. Found: C, 55.46; H, 3.52; N, 22.85; S, 8.68.
2.1.20. N-(4-Fluorobenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.20)
Yield = 82%; mp = 192–194 C; 1H NMR: d (ppm): 8.75
(unsplit, 1H, NH), 8.55 (d, J= 7.17 Hz, 1H, H-10), 8.02–
7.86 (m, 2H, H-7,9), 7.80 (t, 1H, H-8), 7.28 (s, 2H, Ph-2,6),
6.95 (t, J= 7.95 Hz, 2H, Ph-3,5), 4.33 (d, 5.28 Hz, 2H,
NHCH2), 4.26 (s, 2H, SCH2). IR (cm
1): 3276, 3077, 2979,
2925, 2851, 1653, 1619, 1606, 1589, 1549, 1507, 1493, 1474,
1449, 1416, 1382, 1358, 1324, 1278, 1216, 1175, 1158, 1142,
1109, 1097, 1058, 1038, 1018, 981, 971, 894, 877, 851, 832,
814, 767, 715, 690, 645. LC–MS: m/z= 369 [M+H]+. Anal.
Calcd. for C17H13FN6OS: C, 55.43; H, 3.56; N, 22.81; S,
8.70. Found: C, 55.41; H, 3.59; N, 22.86; S, 8.66.
2.1.21. N-(2-Chlorobenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.21)
Yield = 77%; mp = 190–192 C; 1H NMR: d (ppm): 8.76
(unsplit, 1H, NH), 8.56 (d, J= 7.85 Hz, 1H, H-10), 8.02–
7.95 (m, 2H, H-7,9), 7.81 (t, J= 7.02 Hz, 1H, H-8), 7.36 (d,
J= 7.66 Hz, 1H, Ph-3), 7.33 (d, J= 7.99 Hz, 1H, Ph-6),
7.20 (t, J= 7.29 Hz, 1H, Ph-5), 7.12 (t, J= 7.35 Hz, 1H,
Ph-4), 4.43 (d, J= 5.65 Hz, 2H, NHCH2), 4.33 (s, 2H,
SCH2). IR (cm
1): 3367, 3324, 3063, 2920, 2849, 1675, 1615,
1585, 1540, 1493, 1472, 1452, 1442, 1418, 1379, 1359, 1316,
1277, 1255, 1208, 1186, 1170, 1159, 1144, 1132, 1108, 1071,1039, 974, 897, 883, 804, 787, 773, 757, 714, 698, 679, 631.
LC–MS: m/z= 385 [M+H]+. Anal. Calcd. for C17H13ClN6-
OS: C, 53.06; H, 3.40; N, 21.84; S, 8.33. Found: C, 53.02; H,
3.45; N, 21.87; S, 8.30.
2.1.22. N-(3-Chlorobenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.22)
Yield = 99%; mp = 200–202 C; 1H NMR: d (ppm): 8.81 (t,
J= 5.03 Hz, 1H, NH), 8.55 (d, J= 7.85 Hz, 1H, H-10),
7.96–7.91 (m, 2H, H-7,9), 7.83–7.77 (m, 1H, H-8), 7.28 (s,
1H, Ph-2), 7.20 (d, J= 5.79 Hz, 3H, Ph-4,5,6), 4.36 (d,
J= 5.88 Hz, 2H, NHCH2), 4.28 (s, 2H, SCH2). IR (cm
1):
3353, 3269, 3051, 3051, 2921, 2851, 2104, 1650, 1618, 1600,
1586, 1555, 1491, 1474, 1452, 1430, 1385, 1360, 1326, 1279,
1228, 1163, 1139, 1109, 1077, 1038, 998, 983, 969, 842, 765,
713, 693, 676, 632. LC–MS: m/z= 385 [M+H]+. Anal.
Calcd. for C17H13ClN6OS: C, 53.06; H, 3.40; N, 21.84; S,
8.33. Found: C, 53.02; H, 3.45; N, 21.80; S, 8.37.
2.1.23. N-(4-Chlorobenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.23)
Yield = 73%; mp = 182–184 C; 1H NMR: d (ppm): 8.78
(unsplit, 1H, NH), 8.56 (d, J= 7.53 Hz, 1H, H-10), 7.95 (d,
J= 7.37 Hz, 1H, H-7), 7.89 (d, J= 8.00 Hz, 1H, H-9), 7.81
(t, J= 7.02 Hz, 1H, H-8), 7.26 (d, J= 7.64 Hz, 2H, Ph-3,5),
7.19 (d, J= 8.04 Hz, 2H, Ph-2,6), 4.33 (d, J= 5.47 Hz, 2H,
NHCH2), 4.26 (s, 2H, SCH2). IR (cm
1): 3285, 3065, 2989,
2927, 2853, 1639, 1617, 1588, 1547, 1492, 1474, 1453, 1410,
1397, 1378, 1322, 1299, 1274, 1248, 1220, 1170, 1138, 1107,
1091, 1067, 1035, 1019, 979, 969, 890, 876, 833, 818, 807,
784, 766, 716, 688, 642. LC–MS: m/z= 385 [M+H]+. Anal.
Calcd. for C17H13ClN6OS: C, 53.06; H, 3.40; N, 21.84; S,
8.33. Found: C, 53.03; H, 3.47; N, 21.81; S, 8.37.
2.1.24. N-(2-Bromobenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.24)
Yield = 84%; mp = 190–192 C; 1H NMR: d (ppm): 8.78
(unsplit, 1H, NH), 8.57 (d, J= 7.04 Hz, 1H, H-10), 8.05–
7.94 (m, 2H, H-7,9), 7.82 (t, J= 7.04 Hz, 1H, H-8), 7.51 (d,
J= 7.16 Hz, 1H, Ph-3), 7.35 (d, J= 6.17 Hz, 1H, Ph-6),
7.20–7.09 (m, 2H, Ph-4,5), 4.38 (d, J= 5.64 Hz, 2H, NHCH2),
4.33 (s, 2H, SCH2). IR (cm
1): 3327, 3274, 3220, 3049, 2921,
1732, 1674, 1651, 1615, 1585, 1540, 1504, 1491, 1469, 1451,
1438, 1416, 1379, 1320, 1277, 1254, 1210, 1187, 1169, 1144,
1107, 1071, 1040, 1023, 983, 972, 898, 881, 802, 787, 772,
756, 715, 697, 673, 631. LC–MS: m/z= 429 [M+H]+. Anal.
Calcd. for C17H13BrN6OS: C, 47.56; H, 3.05; N, 19.58; S,
7.47. Found: C, 47.52; H, 3.08; N, 19.56; S, 7.49.
2.1.25. N-(3-Bromobenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.25)
Yield = 73%; mp = 194–196 C; 1H NMR: d (ppm): 8.80
(unsplit, 1H, NH), 8.55 (d, J= 7.66 Hz, 1H, H-10), 7.97–7.92
(m, 2H, H-7,9), 7.80 (t, J= 5.87 Hz, 1H, H-8), 7.43 (s, 1H,
Ph-2), 7.33 (d, J= 7.54 Hz, 1H, Ph-4), 7.25 (d, J= 7.33 Hz,
1H, Ph-6), 7.15 (t, J= 7.57 Hz, 1H, Ph-5), 4.35 (d,
J= 5.48 Hz, 2H, NHCH2), 4.28 (s, 2H, SCH2). IR (cm
1):
3271, 3086, 3048, 2987, 2921, 2852, 1650, 1618, 1587, 1571,
1556, 1492, 1475, 1452, 1428, 1385, 1361, 1327, 1280, 1228,
1166, 1140, 1110, 1071, 1038, 1024, 998, 983, 970, 911, 911,
Potential of N-aryl(benzyl,heteryl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)acetamides 797888, 877, 829, 829, 784, 766, 732, 714, 687, 667, 646, 632. LC–
MS: m/z= 429 [M+H]+. Anal. Calcd. for C17H13BrN6OS:
C, 47.56; H, 3.05; N, 19.58; S, 7.47. Found: C, 47.59; H, 3.08;
N, 19.54; S, 7.44.
2.1.26. N-(4-Bromobenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)acetamide (1.26)
Yield = 66%; mp = 168–170 C; 1H NMR: d (ppm): 8.78
(unsplit, 1H, NH), 8.55 (d, J= 7.61 Hz, 1H, H-10), 7.98 (d,
J= 7.54 Hz, 1H, H-7), 7.88 (d, J= 7.92 Hz, 1H, H-9), 7.80
(t, J= 7.23 Hz, 1H, H-8), 7.33 (d, J= 8.01 Hz, 2H, Ph-3,5),
7.21 (d, J= 7.69 Hz, 2H, Ph-2,6), 4.32 (d, J= 5.28 Hz, 2H,
NHCH2), 4.26 (s, 2H, SCH2). IR (cm
1): 3275, 3079, 2985,
2935, 1722, 1690, 1650, 1619, 1588, 1553, 1535, 1489, 1475,
1453, 1433, 1418, 1377, 1349, 1326, 1278, 1228, 1157, 1108,
1071, 1038, 1012, 983, 969, 892, 827, 792, 765, 737, 715, 688,
668, 647, 617. LC–MS: m/z= 429 [M+H]+. Anal. Calcd.
for C17H13BrN6OS: C, 47.56; H, 3.05; N, 19.58; S, 7.47.
Found: C, 47.54; H, 3.09; N, 19.54; S, 7.44.
2.1.27. N-(2-(Triﬂuoromethyl)benzyl)-2-(tetrazolo[1,5-
c]quinazolin-5-ylthio)acetamide (1.27)
Yield = 80%; mp = 180–182 C; 1H NMR: d (ppm): 8.82
(unsplit, 1H, NH), 8.57 (d, J= 7.72 Hz, 1H, H-10), 8.04–
7.96 (m, 2H, H-7,9), 7.82 (t, J= 7.28 Hz, 1H, H-8), 7.63 (d,
J= 6.71 Hz, 1H, Ph-3), 7.54 (d, J= 7.00 Hz, 1H, Ph-6),
7.39 (dd, J= 12.30, 6.02 Hz, 2H, Ph-4,5), 4.55 (d,
J= 4.93 Hz, 2H, NHCH2), 4.34 (s, 2H, SCH2). IR (cm
1):
3272, 3082, 3003, 2922, 2851, 1731, 1653, 1621, 1589, 1556,
1493, 1477, 1454, 1434, 1384, 1313, 1274, 1230, 1212, 1195,
1172, 1163, 1118, 1096, 1072, 1058, 1037, 968, 900, 804, 785,
766, 731, 714, 688, 656, 630. LC–MS: m/z= 419 [M+H]+.
Anal. Calcd. for C18H13F3N6OS: C, 51.67; H, 3.13; N, 20.09;
S, 7.66. Found: C, 51.65; H, 3.16; N, 20.07; S, 7.63.
2.1.28. N-(4-(Triﬂuoromethyl)benzyl)-2-(tetrazolo[1,5-
c]quinazolin-5-ylthio)acetamide (1.28)
Yield = 66%; mp = 192–194 C; 1H NMR: d (ppm): 8.86
(unsplit, 1H, NH), 8.56 (d, J= 7.98 Hz, 1H, H-10), 7.96–7.89
(m, 2H, H-7,9), 7.81 (t, J= 7.52 Hz, 1H, H-8), 7.47 (q,
J= 7.73, 7.50 Hz, 4H, Ph-2,3,5,6), 4.43 (d, J= 5.35 Hz, 2H,
NHCH2), 4.29 (s, 2H, SCH2). IR (cm
1): 3278, 3080, 2985,
2922, 2852, 1750, 1650, 1620, 1588, 1553, 1493, 1475, 1454,
1431, 1385, 1327, 1280, 1230, 1156, 1108, 1069, 1038, 1021,
983, 969, 833, 815, 768, 754, 729, 715, 689, 668, 649. LC–MS:
m/z= 419 [M+H]+. Anal. Calcd. for C18H13F3N6OS: C,
51.67; H, 3.13; N, 20.09; S, 7.66. Found: C, 51.69; H, 3.11; N,
20.13; S, 7.67.
2.1.29. 2-(Tetrazolo[1,5-c]quinazolin-5-ylthio)-N-(thiazol-2-
yl)acetamide (1.29)
Yield = 97%; mp = 232–234 C; 12.57 (s, 1H, NH), 8.54 (d,
J= 3.8 Hz, 1H, H-10), 7.94 (s, 2H, H-7,9), 7.79 (s, 1H, H-8),
7.45 (s, 1H, NCH), 7.10 (s, 1H, SCH), 4.55 (s, 2H, SCH2). IR
(cm1): 3743, 3197, 3118, 3064, 3046, 2918, 2849, 2725, 1688,
1616, 1583, 1556, 1486, 1472, 1450, 1383, 1327, 1266, 1246,
1210, 1174, 1140, 1107, 1074, 1037, 971, 904, 879, 844, 820,
773, 724, 711, 682, 668, 637, 623. Anal. Calcd. for C13H9N7OS2:
C, 45.47;H, 2.64;N, 28.55; S, 18.68. Found:C, 45.44;H, 2.68;N,
28.51; S, 18.71.2.1.30. 2-(Tetrazolo[1,5-c]quinazolin-5-ylthio)-N-(1,3,4-
thiadiazol-2-yl)acetamide (1.30)
Yield = 92%; mp = 242–244 C; 1H NMR: d (ppm) 13.06 (s,
1H, NH), 9.09 (s, 1H, NCH), 8.51 (d, J= 7.6 Hz, 1H, H-10),
7.94 (s, 1H, H-7), 7.89–7.80 (m, 2H, H-8,9), 4.81 (s, 2H,
SCH2). IR (cm
1): 3177, 3094, 3043, 2918, 2849, 2732, 1705,
1615, 1576, 1492, 1473, 1450, 1380, 1338, 1277, 1266, 1252,
1229, 1175, 1140, 1104, 1052, 1040, 974, 907, 892, 880, 822,
775, 714, 687, 639, 606. Anal. Calcd. for C12H8N8OS2: C,
41.85; H, 2.34; N, 32.54; S, 18.62. Found: C, 41.81; H, 2.37;
N, 32.53; S, 18.67.
2.1.31. N-(6-Methylbenzo[d]thiazol-2-yl)-2-(tetrazolo[1,5-
c]quinazolin-5-ylthio)acetamide (1.31)
Yield = 51%; mp = 216–218 C; 1H NMR: d (ppm): d 12.69
(s, 1H, NH), 8.53 (d, J= 7.6 Hz, 1H, H-10), 7.91 (dd,
J= 18.0, 7.7 Hz, 2H, H-7,9), 7.75 (t, J= 7.2 Hz, 1H, H-8),
7.61 (d, J= 6.6 Hz, 2H, Ph-4,7), 7.19 (d, J= 8.0 Hz, 1H,
Ph-5), 4.57 (s, 2H, SCH2), 2.45 (s, 3H, CH3). IR (cm
1):
3275, 3079, 2985, 2935, 1722, 1690, 1650, 1619, 1588, 1553,
1535, 1489, 1475, 1453, 1433, 1418, 1377, 1349, 1326, 1278,
1228, 1157, 1108, 1071, 1038, 1012, 983, 969, 892, 827, 792,
765, 737, 715, 688, 668, 647, 617. Anal. Calcd. for C18H13N7-
OS2: C, 53.06; H, 3.22; N, 24.06; S, 15.74. Found: C, 53.04;
H, 3.26; N, 24.04; S, 15.78.
2.1.32. N-(6-Methoxybenzo[d]thiazol-2-yl)-2-(tetrazolo[1,5-
c]quinazolin-5-ylthio)acetamide (1.32)
Yield = 98%; mp = 236–238 C; 1H NMR: d (ppm): 12.99–
12.57 (s, 1H, NH), 8.51 (d, J= 7.76 Hz, 1H, H-10), 7.95–
7.88 (m, 2H, H-7,9), 7.77 (t, J= 7.89 Hz, 1H, H-8), 7.63 (d,
J= 8.69 Hz, 1H, OCH3CCHCH), 7.38 (s, 1H, CHCOCH3),
6.97 (d, J= 8.65 Hz, 1H, OCH3CCHCH), 4.56 (s, 2H,
SCH2), 3.80 (d, J= 2.81 Hz, 3H, OCH3). IR (cm
1): 3353,
3259, 3211, 3024, 2938, 2838, 1694, 1681, 1643, 1610, 1589,
1557, 1471, 1454, 1434, 1378, 1332, 1315, 1282, 1257, 1225,
1190, 1164, 1113, 1058, 1027, 983, 966, 900, 828, 799, 770,
714, 691, 665, 635. MS: m/z= 424 [M+H]+. Anal. Calcd.
for C18H13N7O2S2: C, 51.05; H, 3.09; N, 23.15; S, 15.14.
Found: C, 51.09; H, 3.03; N, 23.11; S, 15.18.
2.1.33. N-(6-Chlorobenzo[d]thiazol-2-yl)-2-(tetrazolo[1,5-
c]quinazolin-5-ylthio)acetamide (1.33)
Yield = 89%; mp = 236–238 C; 1H NMR: d (ppm): 12.92 (s,
1H, NH), 8.54 (d, J= 7.15 Hz, 1H, H-10), 7.98–7.88 (m, 3H,
H-7,9, CHCl), 7.83–7.76 (m, 1H, H-8), 7.74 (d, J= 8.45 Hz,
1H, CHCHCl), 7.40 (d, J= 8.10 Hz, 1H, CHCHCl), 4.61 (s,
2H, SCH2). IR (cm
1): 3744, 3257, 3174, 3120, 3079, 3063,
2994, 2924, 2849, 2175, 2116, 1693, 1619, 1587, 1548, 1491,
1476, 1446, 1434, 1376, 1330, 1308, 1256, 1220, 1156, 1110,
1097, 1054, 1035, 981, 965, 874, 803, 767, 752, 715, 685, 667,
634. Anal. Calcd. for C17H10ClN7OS2: C, 47.72; H, 2.36; N,
22.91; S, 14.99. Found: C, 47.68; H, 2.34; N, 22.96; S, 15.03.
3. Biological assays
3.1. Bioluminescence inhibition test
The marine luminescent bacteria Photobacterium leiognathi
strain Sh1, isolated from the Azov Sea Shrimp, were used
798 O.M. Antypenko et al.for the bioluminescence analysis. They were cultivated at the
nutrient environment containing (g/L): pepton – 5, yeast
extract – 1.5, meat extract – 1.5, sodium chloride – 30, pH
7.4. In acute action test (inhibiting luminescence) bacteria were
diluted with 3% sodium chloride solution up to concentration
105 cell/mL. The 5–50 lg/mL of the studied substances sus-
pended in DMSO was mixed with 1 mL of the diluted bacterial
suspension. Vials were incubated for 10 min at 25 C, then
intensity of bioluminescence was measured in% relatively to
control tests which were prepared without the studied com-
pounds. In chronic action test (inhibiting growth and lumines-
cence) growth environment was added to the eventual breeding
1:50 and was incubated for 16–18 h at 30 C, whereupon inten-
sity of bioluminescence was measured as well as in the previous
method. Tetracycline was used as a reference. The bacterial
luminescence was measured with Bioluminometer BLM-8801
(«Science», Krasnoyarsk, Russia).
3.2. Antimicrobial and antifungal test
All the newly synthesized compounds were evaluated for their
in vitro antibacterial activity in the Zaporozhyae Regional
Hospital Bacterial Laboratory against Gram positive bacteria
(S. aureus ATCC 25923, Enterococcus faecalis ATCC 29212),
Gram negative bacteria (Enterobacter aerogenes 12, P. aerugin-
osa ATCC 27853, E. coli ATCC 25922, K. pneumoniae 68).
They were also evaluated for their in vitro antifungal potential
against Candida albicans ATCC 885653. The amount of micro-
bial cells was 1.5 · 108 cfu/mL. Incubation period of bacteria
was 24 h at 35 C, yeast – 48–72 h at 28–30 C. The agar-diffu-
sion method was used for the determination of the preliminary
antibacterial and antifungal activity. Standard sterilized ﬁlter
paper disks (6 mm diameter) impregnated with a solution of
the test compound in DMSO (100 lg/disk) were placed on
an agar (Mu¨ller–Hinton Broth (Oxoid)) plate seeded with the
appropriate test organism in triplicates. DMSO alone was used
as control at the same above-mentioned concentration. Ampi-
cillin, Ceftazide, Amikacin, Gentamycin, Ceftriaxone and Nys-
tatin were used as reference drugs. The results were recordedN
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3.3. Antitumor activity
Primary anticancer assay was performed against human tumor
cell line panel derived from nine neoplastic diseases, in accor-
dance with the protocol of the Drug Evaluation Branch,
National Cancer Institute, Bethesda (Boyd and Paull, 1995;
Boyd, 1997). The human tumor cell lines of the cancer screen-
ing panel were grown in RPMI 1640 medium containing 5%
fetal bovine serum and 2 mM L-glutamine. For a typical
screening experiment, cells were inoculated in 96 well microti-
ter plates in 100 mL assay volume, at plating densities ranging
from 5000 to 40000 cell/well. After cell inoculation, the micro-
titer plates were incubated at 37 C, under an atmosphere of
5:95 CO2:air (v/v) at 100% relative humidity, for 24 h prior
to addition of drugs under assessment. Following drug addi-
tion (1 lM), the plates were incubated for an additional 48 h,
under the same conditions. Sulforhodamine B (SRB) solution
(100 lL, 0–4% w/v in 1% aq. acetic acid) was added to each
well and plates were incubated for 10 min at room tempera-
ture. The percentage growth was evaluated spectrophotometri-
cally versus controls not treated with test agents.4. Results and discussion
4.1. Chemistry
Synthesis of the starting compound – potassium salt of tetraz-
olo[1,5-c]quinazolin-5-thion (a) was described in our previous
work (Antypenko et al., 2013). The acetamides 1.1–1.33 were
obtained by known methods: by aminolysis of activated acetic
acid b with N,N-carbonyldiimidazole (CDI) (method A), or by
alkylation of tetrazolo[1,5-c]quinazolin-5-thion potassium salt
with proper halogen derivatives (method B) (Scheme 1,
Table 1).N
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tetrazolo[1,5-c]quinazolin-5-ylthio)acetamides.
Table 1 Radicals of the synthesized compounds.
Compd. R R1 n Compd. R R1 n
1.1 2-OCH3 – 0 1.18 2-F – 1
1.2 3-OCH3 – 0 1.19 3-F – 1
1.3 4-OCH3 – 0 1.20 4-F – 1
1.4 2-F – 0 1.21 2-Cl – 1
1.5 3-F – 0 1.22 3-Cl – 1
1.6 4-F – 0 1.23 4-Cl – 1
1.7 2-Cl – 0 1.24 2-Br – 1
1.8 3-Cl – 0 1.25 3-Br – 1
1.9 4-Cl – 0 1.26 4-Br – 1
1.10 2-Br – 0 1.27 2-CF3 – 1
1.11 3-Br – 0 1.28 4-CF3 – 1
1.12 4-Br – 0 1.29 – – –
1.13 3-CF3 – 0 1.30 – – –
1.14 4-CF3 – 0 1.31 – 6-methyl-1,3-benzothiazol-2-yl –
1.15 2-OCH3 – 1 1.32 – 6-methoxybenzo[d]thiazol-2-yl –
1.16 3-OCH3 – 1 1.33 – 6-chlorobenzo[d]thiazol-2-yl –
1.17 4-OCH3 – 1
Table 2 Values of BL in acute action test (%). The substances
with bold values have shown the most signiﬁcant activities.
Compd.a Concentration (mg/mL)
0 0.025 0.1 0.25
1.1 100.0 62.3 39.0 42.9
1.2 100.0 87.0 52.2 17.4
1.3 100.0 49.1 5.8 0.0
1.4 100.0 39.58 4.17 0.0
1.5 100.0 52.2 8.7 0.0
1.6 100.0 32.2 6.2 2.5
1.7 100.0 58.0 32.4 0.0
1.8 100.0 85.7 47.9 15.1
1.9 100.0 60.0 5.3 1.8
1.10 100.0 25.7 7.4 3.7
1.11 100.0 90.8 32.8 15.1
1.12 100.0 76.3 27.7 13.9
1.13 100.0 99.2 34.6 11.5
1.14 100.0 79.3 45.9 27.3
1.15 100.0 124.0 21.1 3.7
1.16 100.0 78.9 58.4 44.2
1.17 100.0 74.0 18.2 77.9
1.18 100.0 73.8 92.3 55.4
1.19 100.0 82.9 95.3 7.1
1.20 100.0 80.6 80.6 80.6
1.21 100.0 139.1 130.4 87.0
1.22 100.0 98.0 91.5 22.9
1.23 100.0 111.5 86.0 89.2
1.24 100.0 98.0 35.9 22.9
1.25 100.0 107.9 80.6 83.1
1.26 100.0 93.75 52.08 20.83
1.27 100.0 90.9 75.3 45.5
1.28 100.0 3.7 22.1 11.0
1.29 100.0 3.2 54.1 54.1
1.30 100.0 66.2 67.5 62.3
1.32 100.0 64.6 41.5 23.1
1.33 100.0 63.5 56.5 8.8
Tetracycline 100.0 80.7 9.1 0.0
DMSO (control) 100.0 141.7 119.6 110.4
a Substance 1.31 was not tested.
Potential of N-aryl(benzyl,heteryl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)acetamides 799The experiment showed that imidazolides were obtained
quite easily with good yields. Acetamides 1.1–1.5 were also
obtained by the alternative approach – alkylation of potassium
salt a with N-aryl-2-chloroacetamides (method B) in water–
propanol-2 mixture (2:1). The last method has a range of
advantages, notably, short duration of time (60–90 min),
quantitative yields and highly pure products. The structure
of all synthesized compounds was evaluated by elemental anal-
ysis and their spectral data (FT-IR, 1H, LC–MS spectra).
LC–MS data conﬁrmed the purity of obtained substances,
demonstrating their appropriately protonated molecular ions
[M+H]+.
FT-IR spectra of N-aryl(benzyl,heteryl)-2-(tetrazolo[1,5-
c]quinazolin-5-ylthio)acetamides (1.1–1.33) were characterized
by high intensive stretching vibrations of symmetric and asym-
metric deformational vibrations of the CH2 group that
appeared at 2952–2847 and 1469–1491 cm1 appropriately.
Amides had intense vibrations of the C‚O group, which were
registered in the range of 1636 to 1684 cm1, and partially
overlapped stretchings of the NH-group, that were observed
at 1619–1636 cm1, and appeared as a doublet. The stretching
vibrations assigned to the NH-band occured in the range of
3353 to 3258 cm1. In addition, amides gave relatively strong
bending band at 1555–1556 cm1, due to the combination of
CN- and NH-vibrations. Moderate absorption at 1319–
1106 cm1 was caused by stretching vibrations of C-C-C,
C-C(=O)-C and C-C-C. All other registered peaks character-
ized the condensed aromatic rings: mCH (3108–3016 cm
1), mCH
(902–649 cm1), mCS (713–604 cm
1), mCS and mCN (1593–
710 cm1).
The signals in the 1H NMR spectra of the synthesized com-
pounds appeared in accordance with the proposed structure:
one-proton doublet of H-10 at 8.57–8.51 ppm, two-proton
multiplet of H-7 and H-9 at 8.03–7.94 ppm and one-proton
triplet of H-8 at 7.83–7.78 ppm, like in the previous results
(Antypenko et al., 2013; Hand et al., 1984). However, for
many compounds aromatic protons of quinazoline were over-
lapped with protons of phenyl- or benzyl-radicals. For com-
pounds with phenyl moiety (1.1–1.14) NH-proton was
observed as a singlet at 10.72–9.56 ppm, and for substances
with benzyl fragment (1.15–1.21, 1.23–1.28) – as an unsplittriplet at 8.82–8.75 ppm. For heteryl substituted substances
NH-proton was shifted to a weaker ﬁeld and was detected at
Table 3 Values of BL in chronic action test (%). The
substances with bold values have shown the most signiﬁcant
activities.
Compd.a Concentration (mg/mL)
0 0.025 0.1 0.25
1.1 100.0 23.1 53.8 92.3
1.2 100.0 159.2 36.7 26.9
1.3 100.0 40.0 52.0 18.0
1.4 100.0 362.8 395.3 0.0
1.5 100.0 122.4 139.6 134.7
1.6 100.0 12.0 80.0 180.0
1.7 100.0 185.7 392.9 642.9
1.8 100.0 27.9 62.8 139.5
1.9 100.0 114.8 32.8 0.0
1.10 100.0 287.4 86.2 0.0
1.11 100.0 45.3 94.2 191.9
1.12 100.0 22.6 11.3 5.7
1.13 100.0 39.5 75.0 136.4
1.14 100.0 36.0 36.0 28.0
1.15 100.0 32.0 20.0 48.0
1.16 100.0 151.7 236.0 188.8
1.17 100.0 323.1 769.2 669.2
1.18 100.0 21.8 36.8 20.5
1.19 100.0 232.8 98.4 85.2
1.20 100.0 80.0 76.0 240.0
1.21 100.0 0.0 46.5 24.5
1.22 100.0 187.5 625.0 750.0
1.23 100.0 89.2 122.2 75.8
1.24 100.0 112.5 187.5 62.5
1.25 100.0 28.0 84.0 332.0
1.26 100.0 51.2 465.1 465.1
1.27 100.0 61.5 769.2 384.6
1.28 100.0 0.0 287.4 287.4
1.29 100.0 79.5 122.2 14.7
1.30 100.0 84.6 46.2 107.7
1.32 100.0 40.9 5.5 5.5
1.33 100.0 111.5 29.5 23.0
Tetracycline 100.0 0 0 0
DMSO (control) 100.0 74.5 127.7 127.7
a Substance 1.31 was not tested.
Table 4 Antimicrobial activity of compounds (100 lg). The substa
Compd. Conc., lg Microorganism/inhibition zone
ECa SA
1.1 100 6* 6
1.5 100 6 6
1.10 100 6 6
1.31 100 6 6
1.33 100 6 6
Ampicillin 10 26 22
Ceftazide 30 29 21
Amikacin 30 21 22
Gentamycin 10 19 22
Ceftriaxone 30 33 33
Nystatin 100 - –
a Escherichia coli (EC), Staphylococcus aureus (SA), Enterobacter aerog
Klebsiella pneumoniae (KP), Candida albicans (CA).
\ «6» – disk diameter, mm; «–» – not done. Other synthesized substan
concentration.
800 O.M. Antypenko et al.13.06–12.57 ppm. Interestingly, that for compound 1.22 NH
proton was registered as a triplet at 8.81 ppm. For compounds
1.16, 1.18–1.20, 1.21–1.27 proton signals of the NHCH2-group
were slightly deshielded by electronegativity of nitrogen and
appeared as a two-proton doublet at 4.43–4.32 ppm. Protons
of SCH2 were deshielded by the carbonyl group and, according
to the published data, should appear at 2.10–2.50 ppm, but
through the inﬂuence of sulfur signals were shifted to a weaker
ﬁeld. So, for compounds 1.1–1.14 protons of the SCH2 group
were recorded as a two-proton singlet at 4.34–4.25 ppm, and
for compounds 1.15–1.28 at 4.55–4.43 ppm. For compounds
with heteryl moiety signal of the SCH2 group was also shifted
to a weaker ﬁeld to 4.81–4.55 ppm. Signals of methoxy and
methyl substituents of synthesized compounds were observed
in a strong ﬁeld at 3.82–3.71 ppm and 2.45 ppm respectively.
4.2. Pharmacology
4.2.1. P. leiognathi bioluminescence inhibition
Among the existing bioassays marine luminous bacteria
P. leiognathi Sh1 rank special place, which combine the advanta-
ges of bioassay and instrumental methods of the analytical signal
recording. In this bioassay toxicity is determined by the change in
the intensity of bioluminescence, which is a quantitative indicator
of bacterial cell vital functions and makes it possible to evaluate
the integral effect of the synthesizedN-aryl(benzyl,heteryl)-2-(tet-
razolo[1,5-c]quinazolin-5-ylthio)acetamides on the living organ-
isms. So, inhibition of bioluminescence (BL) in acute (Table 2)
and chronic action tests (inhibiting BL and growth, Table 2)
was studied.
The results of bioluminescence research showed that lumi-
nescent bacteria were sensitive to synthesized compounds in
both tests (Tables 2 and 3). Among N-phenyl-2-(tetrazolo[1,
5-c]quinazolin-5-ylthio)acetamides compounds 1.3, 1.4, 1.6,
1.10, 1.15 had the highest inhibition properties (inhibition of
the growth up to 50%) at concentration 0.025 mg/ml in acute
test. It is interesting, that only N-benzyl substituted com-
pounds, namely 1.15, 1.21, 1.23, and 1.25 at concentration
0.025 mg/ml possessed the promotion of BL while introductionnces with bold values have shown the most signiﬁcant activities.
diameter (mm)
EA EF PA KP CA
6 6 6 8 6
6 6 6 8 6
6 6 6 7 6
6 6 6 7 6
6 6 6 8 6
16 17 * – –
– – 25 – –
– – 27 – –
7 9 28 – –
– – 25 25 –
– – – – 21
enes (EA), Enterococcus faecalis (EF), Pseudomonas aeruginosa (PA),
ces exhibited no antimicrobial and antifungal activities in the given
Table 5 Percentage of in vitro tumor cell line growth at 10 lM for compounds.
Compd. Mean growth, % Range of growth, % Most sensitive cell line growth, %*
1.1 100.14 78.28–128.35 88.59 (CCRF-CEM/L), 92.21 (HOP-62/nscLC), 91.76 (NCI-H226/nscLC), 93.28
(NCI-H322 M/nscLC), 93.34 (HCT-15/CC), 91.19 (SF-295/CNSC), 95.12 (SNB-75/
CNSC), 93.01 (UACC-62/M), 94.47 (OVCAR-8/OC), 78.28 (UO-31/RC), 93.06 (PC-
3/PC), 94.67 (MDA-MB-231/ATCC/BC), 95.09 (T-47D/BC)
1.2 101.75 85.58–127.13 88.47 (CCRF-CEM/L), 94.61 (NCI-H322 M/nscLC), 95.93 (HCT-116/CC), 93.84
(SNB-19/CNSC), 87.63 (SNB-75/CNSC), 91.76 (UACC-62/M), 95.27 (OVCAR-8/
OC), (A498/ATCC/RC) 90.23, 85.58 (UO-31/RC), 93.39 (MCF7/BC)
1.3 102.53 83.30–115.54 94.98 (CCRF-CEM/L), 93.79 (HL-60(TB)/L), 93.44 (NCI-H226/nscLC), 90.49 (NCI-
H322 M/nscLC), 93.66 (SNB-19/CNSC), 88.22 (SNB-75/CNSC), 93.78 (U251/
CNSC), 95.66 (UACC-257/M), 91.32 (A498/ATCC/RC), 95.34 (RXF 393/RC), 93.63
(SN12C/RC), 91.62 (UO-31/RC), 94.75 (MCF7/BC), 83.30 (BT-549/BC), 87.52 (T-
47D/BC)
1.5 101.12 82.16–124.56 93.39 (CCRF-CEM/L), 92.90 (HL-60(TB)/L), 93.84 (SR/L), 84.20 (HOP-62/nscLC),
95.27 (HCT-15/CC), 93.41 (SF-295/CNSC), 95.83 (U251/CNSC), 92.63 (UACC-257/
M), 94.40 (UACC-62/M), 90.56 (OVCAR-8/OC), 93.28 (CAKI-1/RC), 82.16 (UO-
31/RC), 94.50 (PC-3/PC), 92.89 (MCF7/BC), 95.15 (MDA-MB-231/ATCC/BC)
1.6 100.50 60.11–129.44 86.19 (NCI-H226/nscLC), 84.70 (HCT-116/CC), 89.15 (HCT-15/CC), 94.07 (SF-539/
CNSC), 95.97 (U251/CNSC), 60.11 (LOX IMVI/M), 91.44 (A498/ATCC/RC), 91.74
(ACHN/RC), 94.84 (CAKI-1/RC), 95.46 (SN12C/RC), 71.88 (MCF7/BC), 95.28
(MDA-MB-231/ATCC/BC), 94.31 (BT-549/BC), 80.53 (MDA-MB-468/BC)
1.7 101.41 80.85–120.07 89.96 (CCRF-CEM/L), 95.83 (RPMI-8226/L), 92.55 (A549/nscLC), 89.53 (HCT-15/
CC), 95.21 (SF-295/CNSC), 94.61 (U251/CNSC), 95.60 (LOX IMVI/M), 93.61 (SK-
MEL-5/M), 95.81 (OVCAR-8/OC), 89.97 (RXF 393/RC), 92.03 (UO-31/RC), 95.00
(BT-549/BC), 84.95 (T-47D/BC), 80.85 (MDA-MB-468/BC)
1.8 98.10 76.42–115.07 91.60 (CCRF-CEM/L), 79.26 (HOP-62/nscLC), 85.92 (NCI-H226/nscLC), 89.54
(NCI-H322 M/nscLC), 95.78 (HCT-15/CC), 92.35 (SF-539/CNSC), 93.24 (SNB-19/
CNSC), 89.42 (SNB-75/CNSC), 93.70 (UACC-257/M), 86.60 (UACC-62/M), 89.35
(IGROV1/OC), 94.71 (OVCAR-4/OC), 95.86 (OVCAR-5/OC), 80.06 (A498/ATCC/
RC), 92.33 (ACHN/RC), 77.45 (CAKI-1/RC), 84.21 (SN12C/RC), 76.42 (UO-31/
RC), 95.85 (PC-3/PC), 81.74 (MCF7/BC), 79.07 (MDA-MB-231/ATCC/BC), 86.23
(MDA-MB-468/BC)
1.9 97.62 81.33–121.49 85.03 (CCRF-CEM/L), 85.83 (HL-60(TB)/L), 90.99 (K-562/L), 91.87 (SR/L), 81.33
(HOP-62/nscLC), 88.99 (NCI-H226/nscLC), 89.18 (SNB-75/CNSC), 93.15 (U251/
CNSC), 88.41 (LOX IMVI/M), 95.00 (SK-MEL-5/M), 90.93 (UACC-62/M), 91.39
(IGROV1/OC), 93.23 (OVCAR-4/OC), 95.33 (OVCAR-5/OC), 90.79 (OVCAR-8/
OC), 89.17 (MCF7/BC), 89.14 (MDA-MB-231/ATCC/BC), 90.13 (T-47D/BC)
1.16 99.68 78.07–113.52 78.07 (CCRF-CEM/L), 95.61 (K-562/L), 88.15 (MOLT-4/L), 92.03 (RPMI-8226/L),
82.45 (SR/L), 79.68 (HOP-62/nscLC), 93.92 (SF-295/CNSC), 89.46 (SK-MEL-2/M),
95.68 (CAKI-1/RC), 76.81 (UO-31/RC), 92.39 (MCF7/BC)
1.17 102.65 83.68–130.77 83.68 (HL-60(TB)/L), 95.94 (K-562/L), 90.63 (SR/L), 95.03 (HCT-15/CC), 90.44
(SNB-75/CNSC), 93.13 (SK-MEL-28/M), 92.72 (SN12C/RC), 86.82 (T-47D/BC)
1.18 99.07 75.07–128.82 91.73 (CCRF-CEM/L), 89.32 (HL-60(TB)/L), 82.41 (K-562/L), 84.98 (MOLT-4/L),
83.69 (SR/L), 79.85 (HOP-62/nscLC), 88.86 (HCT-116/CC), 92.90 (SNB-75/CNSC),
94.91 (LOX IMVI/M), 91.70 (SK-MEL-2/M), 87.57 (SK-OV-3/OC), 93.47 (ACHN/
RC), 93.57 (CAKI-1/RC), 92.00 (TK-10/RC), 75.07 (UO-31/RC), 92.27 (PC-3/PC),
94.14 (MCF7/BC), 94.05 (T-47D/BC)
1.19 97.98 38.33–119.50 81.21 (CCRF-CEM/L), 90.07 (HL-60(TB)/L), 95.43 (K-562/L), 89.44 (RPMI-8226/
L), 95.91 (SR/L), 87.47 (HCT-116/CC), 94.79 (HCT-15/CC), 91.33 (SNB-75/CNSC),
38.33 (LOX IMVI/M), 90.35 (UACC-257/M), 94.10 (UACC-62/M), 94.28 (OVCAR-
4/OC), 95.67 (ACHN/RC), 92.65 (SN12C/RC), 94.35 (UO-31/RC), 86.47 (PC-3/PC),
85.30 (MCF7/BC), 95.77 (T-47D/BC), 89.42 (MDA-MB-468/BC)
1.20 96.52 78.61–115.94 92.60 (CCRF-CEM/L), 86.71 (HL-60(TB)/L), 91.33 (K-562/L), 85.20 (RPMI-8226/
L), 92.38 (NCI-H226/nscLC), 91.48 (HCT-116/CC), 94.98 (HCT-15/CC), 90.11
(HT29/CC), 93.58 (SNB-75/CNSC), 90.85 (U251/CNSC), 82.96 (LOX IMVI/M),
95.29 (MALME-3 M/M), 90.69 (M14/M), 92.94 (SK-MEL-5/M), 86.96 (UACC-257/
M), 93.67 (IGROV1/OC), 89.72 (OVCAR-4/OC), 91.21 (OVCAR-8/OC), 91.13 (786–
0/RC), 92.85 (A498/RC), 83.14 (RXF 393/RC), 95.23 (UO-31/RC), 81.22 (PC-3/PC),
93.22 (MCF7/BC), 94.97 (BT-549/BC), 78.61 (MDA-MB-468/BC)
1.23 99.58 79.68–125.33 79.68 (HL-60(TB)/L), 88.13 (K-562/L), 95.47 (HCT-116/CC), 95.95 (HCT-15/CC),
95.82 (SF-539/CNSC), 93.54 (U251/CNSC), 91.98 (OVCAR-4/OC), 85.17 (UO-31/
RC), 90.05 (PC-3/PC), 95.74 (MCF7/BC), 93.93 (MDA-MB-231/ATCC/BC), 94.99
(BT-549/BC), 86.44 (T-47D/BC), 87.50 (MDA-MB-468/BC)
(continued on next page)
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Table 5 (continued)
Compd. Mean growth, % Range of growth, % Most sensitive cell line growth, %*
1.29 95.51 70.31–114.09 77.61 (CCRF-CEM/L), 95.56 (MOLT-4/L), 84.37 (RPMI-8226/L), 93.13 (SR/L),
79.63 (HOP-62/nscLC), 91.73 (NCI-H226/nscLC), 95.40 (HCT-116/CC), 93.05
(KM12/CC), 85.29 (SF-295/CNSC), 95.63 (SF-539/CNSC), 78.17 (SNB-75/CNSC),
91.85 (LOX IMVI/M), 95.90 (MALME-3 M/M), 93.22 (UACC-257/M), 95.83
(UACC-62/M), 83.08 (IGROV1/OC), 91.03 (SK-OV-3/OC), 81.51 (CAKI-1/RC),
90.46 (SN12C/RC), 70.31 (UO-31/RC), 71.81 (MCF7/BC), 95.57 (MDA-MB-231/
ATCC/BC), 85.34 (T-47D/BC), 79.75 (MDA-MB-468/BC)
1.30 96.97 72.69–122.59 72.69 (CCRF-CEM/L), 86.01 (HL-60(TB)/L), 89.84 (K-562/L), 91.05 (MOLT-4/L),
92.57 (RPMI-8226/L), 83.80 (SR/L), 94.03 (A549/nscLC), 95.28 (NCI-H322 M/
nscLC), 95.08 (HCT-116/CC), 91.77 (HCT-15/CC), 92.29 (SF-539/CNSC), 91.25
(MDA-MB-435/M), 95.16 (UACC-257/M), 94.03 (UACC-62/M), 88.50 (OVCAR-8/
OC), 92.78 (786–0/RC), 91.86 (ACHN/RC), 91.58 (CAKI-1/RC), 86.99 (RXF 393/
RC), 75.37 (UO-31/RC), 90.52 (MCF7/BC), 94.56 (BT-549/BC), 76.33 (T-47D/BC),
89.16 (MDA-MB-468/BC)
1.31 93.51 31.40–124.47 87.80, (CCRF-CEM/L), 85.60 (RPMI-8226/L), 95.58 (SR/L), 89.56 (HOP-62/nscLC),
82.98 (NCI-H226/nscLC), 87.27 (NCI-H322 M/nscLC), 92.58 (NCI-H460/nscLC),
94.26 (HCT-116/CC), 89.31 (HCT-15/CC), 89.01 (KM12/CC), 31.40 (LOX IMVI/
M), 94.58 (M14/M), 87.93 (SK-MEL-2/M), 81.44 (SK-MEL-5/M), 83.78 (UACC-62/
M), 89.86 (IGROV1/OC), 95.63, (OVCAR-3/OC), 87.67 (OVCAR-4/OC), 91.94
(OVCAR-5/OC), 92.20 (SK-OV-3/OC), 87.37 (ACHN/RC), 91.45 (CAKI-1/RC),
93.76 (SN12C/RC), 76.58 (UO-31/RC), 91.03 (PC-3/PC), 64.41 (MCF7/BC), 69.95
(MDA-MB-231/ATCC/BC), 73.65 (T-47D/BC), 70.98 (MDA-MB-468/BC)
1.32 83.53 29.66–120.96 70.35 (CCRF-CEM/L), 86.96 (HL-60(TB)/L), 80.44 (K-562/L), 75.53 (MOLT-4/L),
77.38 (RPMI-8226/L), 47.33 (SR/L), 64.43 (A549/nscLC), 81.25 (HOP-62/nscLC),
92.06 (NCI-H23/nscLC), 86.46 (NCI-H322 M/nscLC), 38.23 (NCI-H460/nscLC),
95.60 (HCC-2998/CC), 79.41 (HCT-15/CC), 31.50 (KM12/CC), 87.91 (SF-268/
CNSC), 16.79 (SF-295/CNSC), 88.85 (SF-539/CNSC), 92.80 (SNB-19/CNSC), 68.01
(U251/CNSC), -29.66 (LOX IMVI/M), 84.06 (M14/M), 92.05 (MDA-MB-435/M),
77.13 (SK-MEL-2/M), 84.52 (UACC-257/M), 73.63 (UACC-62/M), 95.28 (OVCAR-
5/OC), 81.75 (OVCAR-8/OC), 87.52 NCI/ADR-RES, 85.99 (SK-OV-3/OC), 85.75
(ACHN/RC), 65.32 (CAKI-1/RC), 87.33 (SN12C/RC), 71.80 (UO-31/RC), 82.16
(PC-3/PC), 95.48 (DU-145/PC), 72.20 (MCF7/BC), 71.08 (MDA-MB-231/ATCC/
BC), 82.45 (T-47D/BC)
1.33 91.30 56.13–113.40 75.35 (CCRF-CEM/L), 80.67 (HL-60(TB)/L), 79.88 (K-562/L), 74.47 (MOLT-4/L),
80.58 (RPMI-8226/L), 73.40 (SR/L), 83.00 (A549/nscLC), 87.28 (HOP-62/nscLC),
93.32 (NCI-H23/nscLC), 94.75 (NCI-H322 M/nscLC), 81.77 (NCI-H460/nscLC),
92.50 (HCT-15/CC), 56.13 (KM12/CC), 93.64 (SF-268/CNSC), 68.87 (SF-295/
CNSC), 92.83 (SNB-19/CNSC), 89.68 (SNB-75/CNSC), 82.71 (U251/CNSC), 95.79
(LOX IMVI/M), 90.71 (MDA-MB-435/M), 84.20 (SK-MEL-2/M), 94.75 (UACC-
257/M), 82.20 (UACC-62/M), 89.79 (IGROV1/OC), 90.74 (OVCAR-4/OC), 95.27
(OVCAR-5/OC), 92.61 (OVCAR-8/OC), 88.45 (SK-OV-3/OC), 89.77 (ACHN/RC),
82.09 (CAKI-1/RC), 83.77 (SN12C/RC), 73.58 (UO-31/RC), 93.30 (PC-3/PC), 69.78
(MCF7/BC), 78.78 (MDA-MB-231/ATCC/BC), 3.07 (T-47D/BC), 89.31 (MDA-MB-
468/BC)
BC, breast cancer; CC, colon cancer; CNSC, CNS cancer; L, leukemia; M, melanoma; nscLC, non-small cell lung cancer; OC, ovarian cancer;
PC, prostate cancer; RC, renal cancer.
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properties.
According to the chronic action test N-benzyl-substituted
compounds 1.4, 1.7, 1.10, 1.17, 1.19, 1.22 and 1.27 exhibited
signiﬁcant promotive BL activity. Such, for compound 1.22
percentage of BL at concentration 0.25 mg/ml was 750% up
to 127.7% of control. It should be noted, that compounds
1.1, 1.6, 1.8, 1.11, 1.13, 1.21 and 1.28 in the chronic test
showed effect of hormesis, inhibiting the intensity of biolumi-
nescence in the smallest concentration (0.025 mg/ml).
Thus, the majority of the substances had negative effect on
the bacteria P. leiognathi Sh1 BL in acute and chronic action
tests, showing toxicity, but the other part demonstrated BL
high stimulation. In comparison to the previous investigatedintroduction of carboxylic acid or aromatic acid ester, 2-
methyl-4-nitrophenyl and ethanone radicals (Antypenko
et al., 2013), substituted with amides compounds had less toxic
effect.
4.2.2. Antimicrobial and antifungal activities
All synthesized compounds were evaluated for their in vitro
antibacterial activity against Gram positive bacteria (S. aureus,
E. faecalis), Gram negative bacteria (E. aerogenes, P. aerugin-
osa, E. coli, K. pneumoniae) and antifungal properties against
C. albicans. The agar-diffusion method was used to determine
the preliminary activity compared to well known reference
antimicrobials. The compounds were dissolved in concentra-
tion of 100 lg/disk in DMSO. And inhibition zone diameter
Potential of N-aryl(benzyl,heteryl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)acetamides 803(IZD, mm) was used as a measure for the antimicrobial activ-
ity (Table 4).
Synthesized compounds have revealed neither high antibac-
terial, nor antifungal activities. It was found that compounds
1.1, 1.5, 1.10, 1.31, 1.33 possessed light activity against Klebsi-
ella pneumonia.
Thus, introduction of acetamide moiety into the 5th posi-
tion of tetrazolo[1,5-c]quinazoline molecule had negative
impact on its antimicrobial properties, comparing the previous
demonstration of the antibacterial activity against E. faecalis,
S. aureus and E. coli, and antifungal activity against C. albi-
cans, when ethylaminodialkyl and chloropropyl substituents
were presented in its structure (Antypenko et al., 2013).
4.2.3. Anticancer assay for preliminary in vitro testing
Among all of the newly synthesized compounds 19 substances,
namely 1.1–1.3, 1.5–1.9, 1.16–1.20, 1.23, 1.29–1.33, were
selected by the National Cancer Institute (NCI) Developmental
Therapeutic Program for the in vitro cell line screening to inves-
tigate their anticancer activity (Boyd and Paull, 1995; Boyd,
1997). The human tumor cell lines were derived from nine dif-
ferent cancer types: leukemia, melanoma, lung, colon, CNS,
ovarian, renal, prostate and breast cancers. Initially, a single
high concentration was used (10 lM) in the full NCI 60-cell
panel. In the screening protocol, each cell line was inoculated
and preincubated for 24–48 h on a microtiter plate. Then test
substances were added to the plate and the culture was incu-
bated for further 48 h. End point determinations were made
with a protein binding dye, sulforhodamine B. Results for each
test agent were reported as the percent growth of the treated
cells when compared to the untreated control cells (Table 5).
The antitumor activity of the compounds was measured
according to a value of 100 that meant no growth inhibition.
A value of 30 would mean 70% growth inhibition. A value
of 0 meant no net growth over the course of the experiment.
A value of 30 would mean 70% lethality. A value of 100
meant all cells were dead.
N -Heteryl-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)acetamides
were found to have the strongest anticancer activity. Thus,
N-(benzo[d]thiazol-2-yl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)
acetamides revealed the highest inhibition properties against
cell of melanoma. Introducing the methoxy group in the C-6
position of benzo[d]thiazole led to the most active compound
N-(6-methoxybenzo[d]thiazol-2-yl)-2-(tetrazolo[1,5-c]quinazo-
lin-5-ylthio)acetamide (1.32), that showed lethal antitumor
activity (10 lM) against cell line LOX IMVI of melanoma.
Replacement of the methoxy group by the methyl group
(1.31) led to the decrease of anticancer activity, and introduc-
tion of chlorine to the benzo[d]thiazole (1.33) caused the loss
of the property. Compound 1.32 besides negative melanomaTable 6 Scoring functions of docked compounds with best afﬁnity
Compd. Consensus score Shape gauss PLP Chem gauss2 Chem gaus
Geﬁtinib 9.00 507.26 56.55 59.78 69.13
Lapatinib 59.00 599.98 61.50 64.46 71.10
1.18 89.00 451.92 47.48 49.47 59.70
1.1 103.00 453.86 47.75 46.66 56.90
1.32 194.00 451.24 38.31 43.75 53.97
1.31 194.00 418.91 43.01 40.97 48.96inﬂuence demonstrated considerable anticancer activity against
leukemia cell line SR to 47.33%, nscLC cell line NCI-H460 to
38.23%, colon cancer KM12 cell line to 31.50% and CNS can-
cer SF-295 cell line to 16.79%.
Speaking about phenyl- and benzyl-substituted compounds,
N-(3-ﬂuorobenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)acet-
amide (1.19) exhibited high inhibition growth percent (38.33%)
against cell line LOX IMVI of melanoma. Phenyl-substituted
compounds exhibited only moderate anticancer effect.
So, it was proved, that N-aryl(benzyl,heteryl)-2-(tetrazol-
o[1,5-c]quinazolin-5-ylthio)acetamides were selective against
cell line LOX IMVI of melanoma, unlike the leukemia
CCRF-CEM cell line of 2-(tetrazolo[1,5-c]quinazolin-5-
ylthio)-1-(p-tolyl)ethanone and corresponding substituted car-
boxylic acids of previous research (Antypenko et al., 2013).
But, unfortunately, all of these compounds still have not satis-
ﬁed the predetermined threshold inhibition criteria to progress
to the 5-dose screen, which was designed to efﬁciently capture
compounds with antiproliferative activity.
4.2.4. Anticancer docking
Knowing that novel 4-anilinoquinazolines (Barbosa et al., 2014;
Shuang et al., 2013), that contained quinazoline moiety,
inhibited EGFR and were analyzed for molecular docking,
ATP-binding site of EGFR (2ITY.pdb) was selected for the
docking study to show potential anticancer mechanism of
N-aryl(benzyl,heteryl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)
acetamides. Research was conducted by the ﬂexible molecular
docking using the software package OpenEye, including related
utilities: Fred Receptor2.2.5, Vida4.1.1, Flipper, Babel3,
Omega2.4.3 and Fred2.2.5 (OpenEye Scientiﬁc Software,
2005). The crystal structure of the enzyme with known quinazo-
line derivative anticancer drug Geﬁtinib was obtained from the
protein data bank.
Docking methodology is described in our recent investiga-
tion (Kovalenko et al., 2013; Antypenko et al., 2013). Scoring
functions, which were used for calculating the afﬁnity, are
present in Table 6.
According to Consensus score compounds N-(2-methoxy-
phenyl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)acetamide (1.1)
and N-(2-ﬂuorobenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)
acetamide (1.18) revealed the highest afﬁnity to a speciﬁc
biological target, but still lower compared with Geﬁtinib and
Lapatinib. Moreover, molecular docking with visual inspec-
tion indicated, that compound 1.18 was bounded to the EGFR
kinase with hydrogen bond: C(O  MET:793:A (2.36 A˚)
(Fig. 1). Yet, preliminary anticancer studies showed, that this
compound did not reveal signiﬁcant activity.
Compound 1.32, the most active one according to the
in vitro cell line screening in the National Cancer Institutecompared to Geﬁtinib and Lapatinib.
s3 Chem score OEchem score Screen score CGO CGT Zapbind
20.41 35.31 126.06 367.45 0.61 25.60
16.22 42.82 131.70 329.62 0.43 29.62
13.36 29.37 101.90 317.69 0.54 24.61
19.36 33.68 107.47 293.39 0.53 20.66
14.71 25.50 100.40 291.95 0.42 24.71
14.98 27.02 99.32 287.15 0.52 24.69
Figure 1 (a) Interaction of Lapatinib with the binding site of EGFR; (b–c) Interaction of compound 1.18, 1.32 with the binding site of
EGFR. H-bond is shown as a yellow line.
804 O.M. Antypenko et al.(NCI), had the moderate data of Consensus score. Considering
these results, it can be assumed, that the most active anticancer
substances’ mechanism of action is of a different nature.
Though, there is a prediction of high afﬁnity of (tetrazol-
o[1,5-c]quinazolin-5-ylthio)acetamides to the EGFR kinase
for their future anticancer investigations.5. Conclusions
The efﬁcient procedures for the synthesis of novel N-aryl
(benzyl,heteryl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)acetamides
were proposed. The substances structures were elucidated by
FT-IR, LC–MS, 1H NMR and elemental analysis data. The
results of bioluminescence research showed that luminescent
bacteria P. leiognathi strain Sh1 were sensitive to synthesized
compounds in acute and chronic action tests, showing bacterio-
static effect. Compounds 1.6–1.8, 1.11, 1.13 and 1.22 in the
chronic test showed effect of hormesis, inhibiting the intensity
of bioluminescence in the smallest concentration (0.025 mg/ml).
The subsequent screening for antibacterial and antifungal
activities in concentration 100 lg revealed light selective effect
against Klebsiella pneumonia of substances 1.1, 1.5, 1.10, 1.31,
1.33. Anticancer assay for preliminary (10 lM) in vitro testing
in NCI showed, that N-(benzo[d]thiazol-2-yl)-2-(tetrazolo[1,5-c]
quinazolin-5-ylthio)acetamides possessed the highest inhibition
properties against cells of melanoma. Compound 1.32 pos-
sessed lethal antitumor activity against LOX IMVI cell line of
melanoma and 1.31 inhibited its growth to 31.40%. Benzyl
N-3-ﬂuorobenzylsubstituted 1.19 exhibited high inhibition
growth percent (38.33%) against the same cell line. So, N-ben-
zyl-(heteryl-)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)acetamides
appeared to be the promising anticancer agents against mela-
noma. Molecular docking studies into the ATP-binding site
of EGFR indicated that compounds could act like Geﬁtinib,
though the strongest anticancer substances had not the highest
Consensus score data. Hence, purposeful design of anticancer
tetrazolo[1,5-c]quinazoline derivatives is going to be continued
among other N-heterylsubstituted acetylamides.Acknowledgements
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